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Abstract The Ets family transcription factor PU.1 is required
for the development of various lymphoid and myeloid cell line-
ages, and regulates the expression of several genes in a cell
type-speci¢c manner. Recently we found that overproduction
of PU.1 in mouse bone marrow-derived mast cell progenitors
induced the expression of monocyte-speci¢c genes. This
prompted us to analyze the functions of each domain of PU.1
in monocyte-speci¢c gene expression, using transfection of mast
cell progenitors with a series of retrovirus vectors for overex-
pression of various truncation mutants. Both the acidic region
and the Ets domain of PU.1 were required for expression of
monocyte-speci¢c genes, and for enhanced interleukin-6 produc-
tion in response to lipopolysaccharide. The Gln-rich region was
suggested to be involved in expression of both MHC class II and
F4/80. On the other hand, when PU.1 protein lacking the PEST
domain was produced in the progenitor cells, expression of
monocyte-speci¢c genes was substantially enhanced, suggesting
that the PEST domain plays a negative role in monocyte-spe-
ci¢c gene expression.
3 2004 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
PU.1 is an Ets family transcription factor involved in mye-
loid and lymphoid cell lineage development. The requirement
for PU.1 in generation of these lineages was demonstrated by
a PU.1-knockout mouse, in which macrophage and B cell
production was abolished, and production of neutrophils
and T cells was delayed [1^3]. Recent analysis of the PU.1-
knockout mouse revealed that PU.1 was required for the de-
velopment of myeloid dendritic cells (DCs) [4,5]. PU.1 is ex-
pressed in multipotent, interleukin (IL)-3-dependent hemato-
poietic progenitor cells, B cells, macrophages, mast cells, and
neutrophils [6]. In mast cells PU.1 is also shown to regulate
expression of the high a⁄nity receptor for IgE (FcORI) [7],
which plays an important role in IgE-mediated allergic reac-
tions. In addition, PU.1 is involved in mast cell-speci¢c gene
regulation in combination with transcription factors GATA-1
and -2 in a mast cell-speci¢c manner [7^9]. Thus, PU.1 may
play a primary role in the allergic response in mast cells.
It has also been reported that PU.1 determines the lineage
commitment of macrophage/B cell [10] and macrophage/neu-
trophil cell fates [11] in a dose-dependent manner, and over-
production of PU.1 in an erythroid cell line induced a lineage
switch to myelomonocytic cells [12]. In our recent analysis,
overproduction of PU.1 in mast cell progenitors induced
monocyte-speci¢c gene expression and caused morphological
changes [13], suggesting that the expression level of PU.1 de-
termines cell fates between mast cells and monocyte as in the
case of macrophage/B cells and macrophage/neutrophils.
PU.1 contains four functional domains (regions), the acidic
region, the Gln-rich region, the PEST domain, and the Ets
domain. PU.1 binds to target DNA via the Ets domain at the
C-terminus, and the acidic and Gln-rich regions are believed
to be necessary for transactivation [6]. However, the function
of each domain is di¡erent depending on the target genes and/
or the di¡erentiation stage of cells. In this study, we analyzed
the function of each domain of PU.1 in monocyte-speci¢c
gene expression by using retrovirus vectors expressing various
truncation mutants of PU.1.
2. Materials and methods
2.1. Cells
Bone marrow cells prepared from BALB/c mice (Japan SLC, Ha-
mamatsu, Japan) were grown in RPMI 1640 (Sigma-Aldrich, St.
Louis, MO, USA) supplemented with 10% heat-inactivated fetal bo-
vine serum (FBS; Sigma-Aldrich), 100 WM minimum essential me-
dium, non-essential amino acids (Invitrogen, San Diego, CA, USA),
100 U/ml penicillin, 100 Wg/ml streptomycin, 100 WM 2-mercaptoeth-
anol, and 10% pokeweed mitogen-stimulated spleen-conditioned me-
dium [14]. A retrovirus packaging cell line, Plat-E [15], was main-
tained in Dulbecco’s modi¢ed Eagle’s medium (Sigma-Aldrich)
supplemented with 10% heat-inactivated FBS, 100 U/ml penicillin,
100 Wg/ml streptomycin, 1 Wg/ml puromycin (Sigma-Aldrich), and 10
Wg/ml blasticidin (Funakoshi, Tokyo, Japan).
2.2. Constructs
A plasmid, pMX-puro-PU.1 [13], was used to generate retrovirus
vector to overproduce wild-type PU.1. To construct the plasmids for
expression of PU.1 deletion mutants, pMX-puro-PU.1-vAcid, pMX-
puro-PU.1-vGln, pMX-puro-PU.1-vPEST, and pMX-puro-PU.1-
vEts, DNA fragments corresponding to the desired domains were
deleted after introduction of restriction endonuclease recognition se-
quences at the corresponding positions of pCR-2F-PU.1 by site-di-
rected mutagenesis.
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2.3. Transfection
Infection of bone marrow-derived cells was performed with previ-
ously reported methods [13,16,17]. In brief, each plasmid of the pMX-
puro series was transiently introduced into Plat-E with Fugene6
(Roche Diagnostics, Indianapolis, IN, USA) to obtain culture media
containing infectious viruses. Bone marrow cells cultivated for 2 weeks
under the conditions described above were incubated with the infec-
tious supernatants for 2 days in the presence of 10 Wg/ml of polybrene
(Sigma-Aldrich). Infected cells were selected by cultivating in the pres-
ence of 1.2 Wg/ml or puromycin for 10^20 days.
2.4. Flow cytometric analysis
Fc receptors on the cell surface were blocked with 2.4G2 (BD
PharMingen, San Diego, CA, USA) before staining. The anti-mouse
antibodies used were FITC-conjugated anti-I-Ad, anti-CD11b, anti-
CD11c, and anti-F4/80, and PE-conjugated anti-c-kit, all of which
were purchased from BD PharMingen. Staining of cells was per-
formed as previously described [18,19], and cell surface expression
of each molecule was analyzed by FACSCalibur (BD Biosciences,
Mountain View, CA, USA).
2.5. Cytokine measurements
Concentrations of IL-6 in the culture supernatant were determined
by ELISA kits after incubation for 6 h with or without lipopolysac-
charide (LPS) (from Escherichia coli ; Sigma-Aldrich) according to the
manufacturer’s instructions (Genzyme Techne, Minneapolis, MN,
USA).
2.6. Cytochemical analysis and electron microscopy
Cells were cytocentrifuged onto glass slides and stained with May-
Gru«nwald-Giemsa staining solution (Muto Pure Chemicals, Tokyo,
Japan). Transfected cells were ¢xed with 2.5% glutaraldehyde in
0.1 M pH 7.4 SRrensen phosphate bu¡er for 1 h at 4‡C, dehydrated
in graded acetone solutions, and embedded in Epok-812 (OKEN,
Ohken shoji, Tokyo, Japan).
3. Results
3.1. E¡ect of truncation of PU.1 on expression of
monocyte-speci¢c gene
To elucidate the roles of domains/regions of PU.1 in mono-
cyte-speci¢c gene expression, we transfected murine bone mar-
row-derived progenitor cells with retrovirus vectors carrying
wild-type and a series of PU.1 mutants (Fig. 1A). In this
system, wild-type and PU.1 mutants were overproduced in
the cells (Fig. 1B).
As we recently reported, overproduction of wild-type PU.1
induced the expression of monocyte-speci¢c genes, such as
MHC class II, CD11b, CD11c, and F4/80, and repressed
the expression of c-kit [13] (Fig. 2). Cells infected with a virus
expressing PU.1-vEts or PU.1-vAcid showed pro¢les similar
to those of the cells infected with the mock virus (Fig. 2). This
observation indicates that the Ets domain and the acidic re-
gion are required for activating monocyte-speci¢c gene expres-
sion and for repressing mast cell-speci¢c gene expression as
observed in the PU.1-overproduction experiment. Because the
Ets domain and the acidic region of Ets family transcription
factors are thought to play roles in DNA binding and trans-
activation, respectively, we concluded that PU.1 binds target
sequences by its Ets domain and exerts its transcription acti-
vation ability derived from the acidic region.
Overproduction of the mutant that lacked the PEST do-
main (PU.1-vPEST) gave expression pro¢les similar to those
observed with wild-type PU.1 for MHC class II, F4/80, and
c-kit. However, the PU.1-vPEST construct exhibited higher
expression of CD11b and CD11c. In contrast, deletion of
the Gln-rich region dramatically decreased expression of
MHC class II and F4/80 but did not a¡ect expression levels
of CD11b and CD11c (Fig. 2). These results suggest that each
domain (region) of PU.1 has an individual role in expression
of these markers.
3.2. IL-6 production in response to LPS
Toll-like receptors (TLRs) are highly conserved proteins
and recognize speci¢c compounds, like LPS, derived from
pathogenic microorganisms. TLR4 signaling activated by
LPS induces monocytes to produce proin£ammatory cyto-
kines including IL-6 [20]. Therefore, IL-6 production by
LPS stimulation in the PU.1-overproducing cells could be
an index showing that the progenitor cells acquired mono-
cyte-like features. To examine whether the transfected cells
responded to LPS, we analyzed the production of IL-6 in
Fig. 1. PU.1 and its derivatives. A: Structure of wild-type or vari-
ous mutants of PU.1. WT, wild-type; vA, PU.1-vAcid (lacking the
acidic region); vQ, PU.1-vGln (lacking the Gln-rich region); vP,
PU.1-vPEST (lacking the PEST domain); vE, PU.1-vEts (lacking
the Ets domain). B: Western blotting analysis for PU.1. Lysates
(5U105 cells per lane) were analyzed by using anti-PU.1 or anti-
FLAG antibody.
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Fig. 2. Phenotypes of bone marrow-derived cells transfected with retrovirus carrying wild-type or various mutant PU.1 cDNAs. Typical results
are shown. Similar results were obtained in ¢ve other independent experiments.
Fig. 3. Responses of transfected cells to stimulation with LPS. IL-6 production by cells stimulated with LPS. Data represent meanWS.D. of
more than three independent experiments, each performed in duplicate.
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the transfected cells after LPS stimulation (Fig. 3). The IL-6
production was markedly increased in cells producing wild-
type PU.1, PU.1-vGln, and PU.1-vPEST. In contrast, the IL-
6 production level was signi¢cantly lower in the cells infected
with the virus directing the overexpression of PU.1-vAcid or
PU.1-vEts, similar to the case of mock-transfected cells.
3.3. Morphological analysis
The morphology of each cell was analyzed by May-Gru«n-
wald-Giemsa staining of cytospun samples and by electron
microscopy (Fig. 4A,B). When transfected with the virus ex-
pressing the PU.1-vAcid and PU.1-vEts genes, the cells were
found to contain numerous granules (Fig. 4A), which is typ-
ical of mast cells. On the other hand, cells that overexpressed
wild-type PU.1, PU.1-vGln, and PU.1-vPEST contained few
granules but showed monocyte-like morphology characterized
by vacuoles in the cytoplasm, eccentric nuclei, and polarized
lamellipodia (Fig. 4A), as observed for mouse macrophages
Fig. 4. Morphology of bone marrow-derived cells transfected with retrovirus carrying wild-type or various mutant PU.1 cDNAs. A: May-
Gru«nwald-Giemsa staining of cytospun cells. U400. B: Electron micrographs of cells. Magni¢cation is 6000U and bar= 1.6 Wm.
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and DCs [21,22]. Under electron microscopy, larger veils and
lamellipodia extending from cell bodies were observed in cells
overexpressing wild-type PU.1, PU.1-vGln, or PU.1-vPEST
but not in the cells overexpressing PU.1-vAcid and PU.1-
vEts (Fig. 4B). From these results we concluded that the
Ets domain and the acidic region of PU.1 are required for
function of this molecule in morphological change.
3.4. Overproduction of PU.1 increases cell number
When the progenitor cells were infected with the retrovirus
carrying cDNA of wild-type PU.1, an increase (1.5^2 times) in
cell number was observed (Fig. 5). A marked increase in cell
number was also observed in the cells infected with a retro-
virus carrying PU.1-vGln, and PU.1-vPEST, whereas an ap-
parent increase in cell number was not observed upon over-
production of PU.1-vEts. These results suggest that PU.1
accelerates survival and proliferation of hematopoietic pro-
genitors through the functions of the acidic region and the
Ets domain, and that the Gln-rich region and the PEST do-
main repress the activating function of PU.1.
4. Discussion
Recently, we found that overproduction of PU.1 induced
monocyte-speci¢c gene expression in mast cell progenitors and
caused morphological changes [13]. In the present study, we
observed the enhancement of IL-6 production in response to
LPS stimulation by the overproduction of PU.1. To elucidate
a role of each domain of PU.1 in these e¡ects, we transfected
mast cell progenitors with a series of retrovirus vectors direct-
ing the expression of various truncation mutants. The acidic
region and the Ets domain were required for induction of
both the monocyte-speci¢c gene expression and the morpho-
logical changes. The involvement of the Ets domain in macro-
phage development, mediating e¡ects such as the enhanced
expression of Mac-1 (CD11b/CD18) and F4/80 and morpho-
logical change, has also been demonstrated in a similar PU.1
truncation analysis [23]. However, in that study, it was re-
ported that the acidic region was not required for the develop-
ment of macrophages, although the requirement of the acidic
region for the transactivating function of PU.1 was also ob-
served in several other studies [10,24^26]. Contradictory re-
sults are also found in the functional analysis of the Gln-rich
region. The Gln-rich region was shown to be required for the
function of PU.1 in most cases [10,12,23,25], but there is also
a report that denies the involvement of the region in the
function [26]. In our study using a retrovirus overexpression
system, the Gln-rich region was critically required for the ex-
pression of F4/80 and involved in the expression of MHC
class II, but not required for the expression of CD11b and
CD11c, suggesting the involvement of the region in a certain
kind of monocyte-speci¢c gene expression. We currently can-
not explain these controversial results. We may assume that
each domain of PU.1 has di¡erent functions, depending on
target gene, lineage and developmental stage of the cells pro-
ducing PU.1.
The PEST domain of PU.1 is reported to serve as the in-
teracting domain with transcription factors such as interferon
regulatory factor (IRF) family transcription factors, IRF-4,
and ICSBP/IRF-8 [27]. We showed that deletion of the
PEST domain did not decrease the expression of monocyte-
speci¢c genes, such as MHC class II and F4/80, nor did it
a¡ect the morphological changes in our PU.1-overproducing
system, suggesting that the domain is not involved in the
changes in the gene expression pro¢le and the cell morphol-
ogy. However, the deletion of the PEST domain resulted in
enhanced expression of CD11b and CD11c. This result sug-
gests that the PEST domain may have a function to repress
the expression of the genes through association with transcrip-
tion factors such as IRF-4 and ICSBP, both of which are
expressed in lymphoid and myeloid cells [28^30]. The produc-
tion level of PU.1-vPEST was shown to be lower than that of
wild-type and other mutants by Western blotting analysis with
anti-FLAG antibody (Fig. 1B and not shown). This suggests
that the changes induced by PU.1-vPEST may have been
underestimated. It should be noted that the PU.1 mutant
lacking the PEST domain also has a higher potential for in-
ducing the proliferation of DC-like monocytes. This ¢nding
may suggest that masking the function of the PEST domain
by some way might be adapted for preparation of DCs, which
is expected to be used in immunotherapeutic approaches for
treating allergies, autoimmune diseases, infectious diseases,
and cancer.
Deletion of the Gln-rich region or the PEST domain caused
a marked increase in transfected cell numbers. The e¡ect is
intriguing, because wild-type PU.1 does not show such a sig-
ni¢cant e¡ect on cell numbers, which is in contrast with the
observation that wild-type and both PU.1 mutants show the
same phenotype in morphology and IL-6 assay. This may
suggest unidenti¢ed functions of the Gln-rich region or the
PEST domain of PU.1 in cell proliferation or apoptosis. At
present, we cannot explain the e¡ect of the deletion on the
increase in cell number. Further detailed analysis such as es-
timation of cell death (apoptosis) and proliferation rate in
various cell population will be required to elucidate the mech-
anism.
The mechanism of enhanced expression of IL-6 in response
to LPS in PU.1-overproducing cells is unclear. A previous
Fig. 5. E¡ects of wild-type and mutants PU.1 on proliferation of in-
fected cells. Cells were counted after cultivation for 20 days in the
presence of puromycin.
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report suggested that PU.1 recognizes the promoter of TLR4
[31]. Therefore one might imagine that the stimulatory signal
of LPS was ampli¢ed in the cells through overproduction of
TLR4. However, this was not the case in this study, because
the level of cell surface expression of TLR4 was not a¡ected
by overproduction of PU.1 (preliminary observation). Previ-
ously it was reported LPS stimulation caused functional and
conformational changes of PU.1 through phosphorylation of
speci¢c Ser residues [32]. This suggests the possibility that
PU.1 is downstream of a TLR4-mediated signal cascade. In-
deed, further analysis will be required to clarify the role of
PU.1 in the production of IL-6.
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